Cabazitaxel and prednisone as second-line therapy of metastatic, castration-resistant prostate cancer

Currently, doctors have at their disposal a number of drugs prolonging life of patients with castration-resistant prostate cancer (CRPC). The majority is approved for use as the 1st line therapy and, in absence of direct comparison, is considered potentially equally effective. Patients with CRPC need continuous treatment for suppression of disease progression resulting in sequential use of therapeutic agents. Modern standards and recommendations do not provide a clear algorithm for prescription, therefore an individual approach is necessary taking in account various factors of a particular case ranging from previous therapies to patients’ preferences. This article considers the most significant factors affecting CRPC therapy selection and ways of therapy optimization in compliance with the established treatment standards and taking into account the list of drugs approved for use in Russia.

Get full-text (via PubEx)

Prognostic impact of prior local therapy in castration-resistant prostate cancer

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hyab019 ◽

2021 ◽

Author(s):

Mikifumi Koura ◽

Masaki Shiota ◽

Shohei Ueda ◽

Takashi Matsumoto ◽

Satoshi Kobayashi ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Local Therapy ◽

Progression Free Survival ◽

Castration Resistant Prostate Cancer ◽

First Line ◽

Free Survival ◽

First Line Therapy ◽

Castration Resistant ◽

Line Therapy

Abstract Objective This study aimed to reveal the prognostic values of prior local therapy in first-line therapy using androgen receptor-axis targeting agents (abiraterone or enzalutamide) or docetaxel for castration-resistant prostate cancer (CRPC). Methods The study included 303 patients treated with first-line therapy for non-metastatic and metastatic CRPC. The association between prior local therapy and therapeutic outcome including progression-free survival and overall survival was investigated by univariate and multivariate analyses as well as propensity score-matched analysis. Results In univariate analysis, local prior therapy was associated with a lower risk of all-cause mortality (hazard ratio, 0.56, 95% confidence interval, 0.40–0.79; P = 0.0009). Overall survival, but not progression-free survival, was better among patients with prior local therapy compared with patients without prior local therapy even after multivariate analysis and propensity score-matched analysis. Conclusions This study robustly indicated that prior local treatment was prognostic for overall survival among patients with CRPC. This finding is useful to predict patient prognosis in CRPC.

Get full-text (via PubEx)

647P Clinical implications of intraductal carcinoma of the prostate sub-patterns in metastatic castration-resistant prostate cancer patients treated with abiraterone or docetaxel as the first-line therapy

Annals of Oncology ◽

10.1016/j.annonc.2020.08.906 ◽

2020 ◽

Vol 31 ◽

pp. S529

Author(s):

W. Zhipeng ◽

S. Zhu ◽

J. Chen ◽

J. Zhao ◽

X. Zhang ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Intraductal Carcinoma ◽

Clinical Implications ◽

Castration Resistant Prostate Cancer ◽

First Line ◽

Carcinoma Of The Prostate ◽

First Line Therapy ◽

Castration Resistant ◽

Line Therapy

Get full-text (via PubEx)